“Biosimilars and Originators of Anti-TNFα Drugs: Similar Safety Profiles but Differences in Retention Rates in Inflammatory Arthropathies Treatment”

https://pubmed.ncbi.nlm.nih.gov/38115772

This study found that while both biosimilars and originators of anti-tumor necrosis factor α drugs had similar safety profiles in treating inflammatory arthropathies, the biosimilar group had a reduced retention rate at 24 months. However, biosimilars can still be considered a valid, safe, and less expensive alternative to originators.